2 results
Approved WMORecruiting
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…
Approved WMORecruiting
Single dosingPrimary objective:• To evaluate the safety and tolerability of single ascending doses of SOL-116 in healthy subjects and rheumatoid arthritis (RA) patients.Secondary objective:• To determine single dose pharmacokinetic (PK)…